Dr. Mark T. Kearns, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 69
Licensed in Colorado since 2008, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Nebraska College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
CO license 46559 (first issued 2008; active) -
Internal Medicine Physician
OH license 35087429 -
Pulmonary Disease Physician
CO license 46559 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Denver Health & Hospital Authority Denver, CO
Medical groups
- Denver Health and Hospital Authority (849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 69
- Services billed
- 168
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 31 | 11 |
| Critical care, first 30-74 minutes | 30 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 17 | 12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | 15 |
| Test to determine lung volumes using sensors | 14 | 14 |
| Test to examine how well the lungs exchange gases | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Denver, CO | 40 |
| Fluticasone Propionate Other prescribers in Denver, CO | 40 |
| Dupixent Pen (dupilumab) Other prescribers in Denver, CO | 33 |
| Montelukast Sodium Other prescribers in Denver, CO | 28 |
| Azithromycin Other prescribers in Denver, CO | 25 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Denver, CO | 22 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Denver, CO | 18 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Denver, CO | 16 |
| Omeprazole Other prescribers in Denver, CO | 15 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Denver, CO | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $217 in total to this clinician.
| Fisher & Paykel Healthcare Inc | $191 |
|---|---|
| Merck Sharp & Dohme LLC | $25.70 |
| Food and Beverage | $191 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jun 24, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.